Memantine Demo (Memantine Hydrochloride)

• Memantine is indicated for neurodegenerative conditions where excessive NMDA receptor activity contributes to neuronal injury.
• Alzheimer’s disease (mild to moderate): helps maintain cognitive function and daily activities.
• Alzheimer’s disease (moderate to severe): supports functional abilities and may slow decline.
• Alzheimer’s disease (any stage): used as part of a comprehensive management plan to improve quality of life.

• Memantine acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor ion channel. By binding within the channel at moderate affinity, it reduces excessive calcium influx caused by over‑activation of glutamate, thereby limiting excitotoxic neuronal damage while preserving normal synaptic transmission essential for learning and memory.

Memantine may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dizziness: transient light‑headedness, especially after dose initiation.
• Headache: mild to moderate intensity, often resolves with continued therapy.
• Constipation: reduced bowel movements, manageable with diet or laxatives.
• Confusion: occasional disorientation, typically improves over time.
• Fatigue: feeling unusually tired, may lessen with dose adjustment.
• Hypertension: modest increase in blood pressure in some patients.

Serious or Rare Side Effects

• Seizures: rare occurrence, requires immediate medical attention.
• Cardiac arrhythmia: irregular heart rhythm, potentially life‑threatening.
• Severe allergic reaction: rash, swelling, or difficulty breathing.
• Hallucinations or psychosis: visual or auditory disturbances.
• Suicidal thoughts: emergent mood changes needing urgent evaluation.
• Liver function abnormalities: elevated enzymes detected on labs.

• Before initiating memantine therapy, several safety considerations should be reviewed.
• Renal impairment: assess kidney function and adjust dose if necessary.
• History of seizures: monitor closely for increased seizure activity.
• Cardiovascular disease: evaluate blood pressure and cardiac status regularly.
• Concurrent NMDA antagonists: avoid combined use to prevent additive CNS effects.
• Pregnancy and lactation: safety not established; weigh potential risks and benefits.
• Store at room temperature: keep in the original container, protect from moisture and light.

Memantine can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

• Amantadine: combined NMDA blockade may intensify central nervous system effects.
• Ketamine: additive antagonism can lead to severe neuropsychiatric reactions.
• High‑dose anticholinergics: may worsen cognitive impairment.

Moderate Interactions (Monitor Closely)

• Diuretics: may increase risk of hypotension.
• Antihypertensives: additive blood‑pressure‑lowering effect.
• CNS depressants (e.g., benzodiazepines): may enhance dizziness and sedation.